| Ariel Stearnes Brooks, MD | |
|
2900 Lamb Cir, Christiansburg, VA 24073-6344 | |
| (540) 731-2000 | |
| (540) 731-2659 |
| Full Name | Ariel Stearnes Brooks |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 7 Years |
| Location | 2900 Lamb Cir, Christiansburg, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508387051 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 0101268649 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carilion Medical Center | Roanoke, VA | Hospital |
| Carilion New River Valley Medical Center | Christiansburg, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carilion Healthcare Corporation | 5890607253 | 408 |
| Carilion Medical Center | 9830096585 | 758 |
News Archive
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.
Breast cancer patients in one of the United States' largest and fastest-growing ethnic minority groups are likely to experience numerous gaps in care following their primary treatment, research from Oregon State University suggests.
A series of illustrations and charts designed as decision aids for parents of children with minor head injuries helped them communicate with emergency medicine physicians and make informed decisions about their child's care, according to a study that will appear Sept. 21 in JAMA Network Open.
The National Institute of Environmental Health Sciences (NIEHS) is awarding $36 million in grants to 20 organizations that develop safety and health training for workers involved in hazardous waste operations and transportation, environmental restoration of contaminated facilities, and chemical emergency response. These training programs can receive annual funding for up to five years.
› Verified 4 days ago
| Entity Name | Carilion Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447206370 PECOS PAC ID: 5890607253 Enrollment ID: O20031106000273 |
News Archive
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.
Breast cancer patients in one of the United States' largest and fastest-growing ethnic minority groups are likely to experience numerous gaps in care following their primary treatment, research from Oregon State University suggests.
A series of illustrations and charts designed as decision aids for parents of children with minor head injuries helped them communicate with emergency medicine physicians and make informed decisions about their child's care, according to a study that will appear Sept. 21 in JAMA Network Open.
The National Institute of Environmental Health Sciences (NIEHS) is awarding $36 million in grants to 20 organizations that develop safety and health training for workers involved in hazardous waste operations and transportation, environmental restoration of contaminated facilities, and chemical emergency response. These training programs can receive annual funding for up to five years.
› Verified 4 days ago
| Entity Name | Carilion Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730123472 PECOS PAC ID: 9830096585 Enrollment ID: O20040107000472 |
News Archive
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.
Breast cancer patients in one of the United States' largest and fastest-growing ethnic minority groups are likely to experience numerous gaps in care following their primary treatment, research from Oregon State University suggests.
A series of illustrations and charts designed as decision aids for parents of children with minor head injuries helped them communicate with emergency medicine physicians and make informed decisions about their child's care, according to a study that will appear Sept. 21 in JAMA Network Open.
The National Institute of Environmental Health Sciences (NIEHS) is awarding $36 million in grants to 20 organizations that develop safety and health training for workers involved in hazardous waste operations and transportation, environmental restoration of contaminated facilities, and chemical emergency response. These training programs can receive annual funding for up to five years.
› Verified 4 days ago
| Entity Name | Carilion Rockbridge Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174636021 PECOS PAC ID: 4789658261 Enrollment ID: O20040820000838 |
News Archive
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.
Breast cancer patients in one of the United States' largest and fastest-growing ethnic minority groups are likely to experience numerous gaps in care following their primary treatment, research from Oregon State University suggests.
A series of illustrations and charts designed as decision aids for parents of children with minor head injuries helped them communicate with emergency medicine physicians and make informed decisions about their child's care, according to a study that will appear Sept. 21 in JAMA Network Open.
The National Institute of Environmental Health Sciences (NIEHS) is awarding $36 million in grants to 20 organizations that develop safety and health training for workers involved in hazardous waste operations and transportation, environmental restoration of contaminated facilities, and chemical emergency response. These training programs can receive annual funding for up to five years.
› Verified 4 days ago
| Entity Name | Carilion Giles Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194718304 PECOS PAC ID: 3678670221 Enrollment ID: O20070516000487 |
News Archive
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.
Breast cancer patients in one of the United States' largest and fastest-growing ethnic minority groups are likely to experience numerous gaps in care following their primary treatment, research from Oregon State University suggests.
A series of illustrations and charts designed as decision aids for parents of children with minor head injuries helped them communicate with emergency medicine physicians and make informed decisions about their child's care, according to a study that will appear Sept. 21 in JAMA Network Open.
The National Institute of Environmental Health Sciences (NIEHS) is awarding $36 million in grants to 20 organizations that develop safety and health training for workers involved in hazardous waste operations and transportation, environmental restoration of contaminated facilities, and chemical emergency response. These training programs can receive annual funding for up to five years.
› Verified 4 days ago
| Entity Name | Lake Spring Physician Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568954287 PECOS PAC ID: 1254689482 Enrollment ID: O20180806000449 |
News Archive
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.
Breast cancer patients in one of the United States' largest and fastest-growing ethnic minority groups are likely to experience numerous gaps in care following their primary treatment, research from Oregon State University suggests.
A series of illustrations and charts designed as decision aids for parents of children with minor head injuries helped them communicate with emergency medicine physicians and make informed decisions about their child's care, according to a study that will appear Sept. 21 in JAMA Network Open.
The National Institute of Environmental Health Sciences (NIEHS) is awarding $36 million in grants to 20 organizations that develop safety and health training for workers involved in hazardous waste operations and transportation, environmental restoration of contaminated facilities, and chemical emergency response. These training programs can receive annual funding for up to five years.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ariel Stearnes Brooks, MD 213 S Jefferson St Ste 625, Roanoke, VA 24011-1713 Ph: (540) 224-5516 | Ariel Stearnes Brooks, MD 2900 Lamb Cir, Christiansburg, VA 24073-6344 Ph: (540) 731-2000 |
News Archive
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.
Breast cancer patients in one of the United States' largest and fastest-growing ethnic minority groups are likely to experience numerous gaps in care following their primary treatment, research from Oregon State University suggests.
A series of illustrations and charts designed as decision aids for parents of children with minor head injuries helped them communicate with emergency medicine physicians and make informed decisions about their child's care, according to a study that will appear Sept. 21 in JAMA Network Open.
The National Institute of Environmental Health Sciences (NIEHS) is awarding $36 million in grants to 20 organizations that develop safety and health training for workers involved in hazardous waste operations and transportation, environmental restoration of contaminated facilities, and chemical emergency response. These training programs can receive annual funding for up to five years.
› Verified 4 days ago
Vishal B. Gohil, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 110 Akers Farm Rd, Christiansburg, VA 24073 Phone: 540-382-9405 Fax: 540-382-2958 | |
Amjad Uzair Wyne, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2900 Lamb Cir, Suite 201, Christiansburg, VA 24073 Phone: 540-731-3172 | |
Dr. Allan H Sklar, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 20 Phoenix Blvd Nw, Christiansburg, VA 24073 Phone: 540-381-3750 Fax: 540-381-3751 | |
Mr. Matthew Benjamin Burns, AG-ACNP Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2900 Lamb Cir Ste 7-700a, Christiansburg, VA 24073 Phone: 540-731-7460 Fax: 540-731-1081 | |
Dr. Thomas Paul Vacek, M.D., M.S. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2900 Lamb Cir Ste 201, Christiansburg, VA 24073 Phone: 540-731-2328 Fax: 540-639-3950 | |
Mrs. Clemence White, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 110 Akers Farm Rd, Christiansburg, VA 24073 Phone: 540-382-9405 Fax: 540-382-2958 | |
Dr. John Mark Lawson, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 110 Akers Farm Rd, Christiansburg, VA 24073 Phone: 540-382-9405 |